Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Electroconvulsive Therapy for Treatment of Alzheimer´s Disease
Authors not listed
Central Institute of Mental Health, Mannheim · 2026
Abstract
Electroconvulsive therapy (ECT) induces a cerebral seizure by electrical stimulation under general anesthesia and muscle relaxation, is regarded as a highly efficient (for specific and severe psychiatric disorders) and extremely safe modern treatment option.
Alzheimer´s disease (AD) is a neurodegenerative disorder which is characterized by progressive cognitive deterioration accompanied by declining activities of daily living, by a variety of behavioral disturbances and by neuropsychiatric symptoms. The clinical progression of disease can be delayed by pharmaceutical therapies like acetylcholinesterase inhibition (e.g. rivastigmine) for 6 to 12 months at most.
Along with the well-known biomarkers of AD (Aß- and tau-proteins) a lower brain-derived neurotrophic factor (BDNF) level is since recently being considered as a negative predictor for the further disease course. In animal experimental studies it was possible to arrest the disease progression with the aid of neurotrophic substances. Many single studies, but also a number of meta-analyses show primary gray matter atrophy in hippocampal, parahippocampal and medial temporal brain regions.
Strikingly, ECT yields exact opposite effects to those caused by AD: an ECT series leads to an increase of serum BDNF-levels in patients. Parallel to this observation evidence exists for gray matter volume gain after an ECT series, especially for the hippocampus.
There is sufficient clinical experience regarding the use of ECT in AD-patients, mainly on the basis of following indications: a) affective disorders and b) behavioral disturbances. A positive effect of ECT on the symptoms of agitation and aggression was assessed in AD patients alongside with a very good tolerability.
To investigate the potential salutary effects of ECT on AD the investigators designed a pilot study with the following concept: Patients with a confirmed AD diagnosis and preexisting stable antidementia medication over at least 6 months will receive a modified maintenance ECT over a total of 27 weeks.
In the proposed pilot study, the investigators hypothesize that cognitive functioning of AD patients will improve significantly and independently from affective symptoms, when initial and final examinations are compared. The affirmation of the hypothesis would provide not only further insight into the mechanism of action of ECT but also a very important reference point for the development of new treatment options for a so-far incurable disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Anonymous. (2026). Electroconvulsive Therapy for Treatment of Alzheimer´s Disease. <em>Central Institute of Mental Health, Mannheim</em>. https://clinicaltrials.gov/study/NCT02438202
Vancouver
Anonymous. Electroconvulsive Therapy for Treatment of Alzheimer´s Disease. Central Institute of Mental Health, Mannheim. 2026.
BibTeX
@misc{anon2026Electr,
title = {Electroconvulsive Therapy for Treatment of Alzheimer´s Disease},
author = {Anonymous},
journal = {Central Institute of Mental Health, Mannheim},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
2012
Preprint · OA
MRI Measures of Neurodegeneration as Biomarkers of Alzheimer's Disease
Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente 2016
Open access · US-GOV
Cognitive, Behavioral and Functional Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Potential Alzheimer Disease: Two Treatment Modalities Comparison
Göteborg University 2024
Open access · US-GOV
Bridging the Gap: Creating a Continuum of Care Through Active Follow-up by a Case Manager After Discharge - a Controlled Study
Journal of Neuroscience 2006
Open access · CC-BY
Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation
Taichung Veterans General Hospital 2012
Open access · US-GOV
Department of Psychiatry, Taichung Veterans General Hospital
University of Texas at Austin 2023
Open access · US-GOV